# Chronic Stress, Diabetes, and Cardiovascular Disease: Epidemiologic Evidence, Pathogenetic Insights, and Therapeutic Strategies

**Authors:** Mahri Hatamova, Mario Rizk, Keston Rattan, Andrew Gaballa, Samy I. McFarlane

PMC · DOI: 10.7759/cureus.102108 · 2026-01-22

## TL;DR

Chronic stress is linked to diabetes and heart disease through complex biological mechanisms, and managing stress may help reduce these health risks.

## Contribution

This review provides updated evidence and mechanistic insights on how chronic stress contributes to diabetes and cardiovascular disease.

## Key findings

- Chronic stress is strongly associated with diabetes, hypertension, and cardiovascular disease.
- Stress activates biological pathways like the HPA axis and RAAS, leading to increased inflammation and blood pressure.
- Evidence-based stress interventions can reduce cardiovascular risk and may be useful in clinical practice.

## Abstract

Chronic stress has been shown in cross-sectional as well as longitudinal studies to be strongly associated with diabetes, hypertension, and cardiovascular disease (CVD). These studies have used various methods of stress assessment. Proposed pathogenetic mechanisms linking psychological distress with diabetes and CVD are complex and include stimulation of the hypothalamic-pituitary-adrenal axis with excess cortisol release, as well as stimulation of the renin-angiotensin-aldosterone system, resulting in elevated blood pressure, in addition to an altered immune system, increased inflammation, and oxidative stress, among others. In this review, we provide the reader with cutting-edge information on the current evidence for the association between chronic psychological stress, diabetes, and CVD, highlighting the major studies addressing this important topic. We also provide a detailed mechanistic overview of the pathogenesis of diabetes and CVD in psychologically stressed individuals, including experimental and laboratory evidence. We finally discuss the major evidence-based therapeutic interventions for psychological stress and their effects on CVD risk reduction, with the aim of presenting these therapeutic options as potentially effective ways to implement in clinical practice.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015), cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** SLC2A4 (solute carrier family 2 member 4) [NCBI Gene 6517] {aka GLUT4}, CAT (catalase) [NCBI Gene 847], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, PRKCB (protein kinase C beta) [NCBI Gene 5579] {aka PKC-beta, PKCB, PKCI(2), PKCbeta, PRKCB1, PRKCB2}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}
- **Diseases:** Insulin Resistance (MESH:D007333), vascular injury (MESH:D057772), ischemic heart disease (MESH:D017202), CVD (MESH:D002318), myocardial infarction (MESH:D009203), Takotsubo cardiomyopathy (MESH:D054549), atherogenesis (MESH:D050197), venous thromboembolism (MESH:D054556), hyperinsulinemia (MESH:D006946), elevated blood pressure (MESH:D006973), mental (MESH:D008607), arterial stiffness (MESH:C566112), thrombosis (MESH:D013927), microvascular (MESH:D017566), MSIMI (MESH:D000079225), traumatic stress (MESH:D040921), abdominal obesity (MESH:D056128), myocardial dysfunction (MESH:D006331), CAD (MESH:D003324), Depression (MESH:D003866), heart failure (MESH:D006333), impaired glucose control (MESH:D007174), T2DM (MESH:D003924), anxiety (MESH:D001007), angina (MESH:D000787), arterial inflammation (MESH:D001167), cancer (MESH:D009369), rupture (MESH:D012421), Diabetes (MESH:D003920), endothelial dysfunction (MESH:D014652), CHD (MESH:D003327), acute coronary syndromes (MESH:D054058), dyslipidemia (MESH:D050171), cardiometabolic multimorbidity (MESH:D024821), hyperglycemia (MESH:D006943), Inflammation (MESH:D007249), traumatic (MESH:D014947), visceral adiposity (MESH:D007418), Chronic Stress (MESH:D013313), Neuroendocrine Dysfunction (MESH:D018358), Psychological Distress (MESH:D012128), metabolic abnormalities (MESH:D008659), ischemia (MESH:D007511), Autonomic Dysregulation (MESH:D021081), Major depressive disorder (MESH:D003865), hypercoagulability (MESH:D019851), stroke (MESH:D020521), type (MESH:D006969), obesity (MESH:D009765), arrhythmias (MESH:D001145), autoimmune disorders (MESH:D001327), gestational diabetes (MESH:D016640)
- **Chemicals:** Catecholamines (MESH:D002395), sodium (MESH:D012964), superoxide (MESH:D013481), canakinumab (MESH:C541220), ROS (MESH:D017382), hexosamine (MESH:D006595), glucose (MESH:D005947), alcohol (MESH:D000438), lipid (MESH:D008055), epinephrine (MESH:D004837), aldosterone (MESH:D000450), Cortisol (MESH:D006854), polyol (MESH:C024617), oxygen (MESH:D010100), norepinephrine (MESH:D009638), free fatty acids (MESH:D005230), advanced glycation end products (MESH:D017127)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12924779/full.md

---
Source: https://tomesphere.com/paper/PMC12924779